Drug Profile
Quinoxapeptin B
Latest Information Update: 13 Feb 2008
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antiretrovirals; Cyclic peptides; Quinoxalines
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 10 Sep 1998 No-Development-Reported for HIV infections treatment in Spain (unspecified route)
- 10 Sep 1998 No-Development-Reported for HIV infections treatment in USA (unspecified route)
- 17 May 1996 Preclinical development for HIV infections treatment in Spain (unspecified route)